Arhant Shah

Arhant Shah is an Investment Banking Analyst currently working at Centerview Partners, specializing in biotech mergers and acquisitions, with notable involvement in the $2.4 billion sale of Fusion Pharmaceuticals to AstraZeneca. Previously, Arhant held the same title at Guggenheim Partners, where contributions included the $478 million sale of Orchard Therapeutics to Kyowa Kirin and Revolution Medicines' $1.1 billion acquisition of EQRx. Early experience includes a summer analyst position at Rothschild & Co, which resulted in a full-time return offer, and serving as an Equity Research Analyst for the Knall-Cohen Investment Fund during studies at the Indiana University Kelley School of Business, where Arhant earned a Bachelor of Science in Business with a focus on Finance and Business Analytics. Prior education includes a high school diploma from West Windsor-Plainsboro High School North.